Cambrex Receives FDA Warning Letter

Cambrex Corporation announced that it has received a warning letter from the U.S. Food and Drug Administration relating to an inspection of the company’s generic active pharmaceutical ingredient manufacturing facility located in Milan, Italy in March 2009.
StreetInsider.com